Sustained Immune Control in HBeAg-Positive Patients who Switched from Entecavir Therapy to Pegylated Interferon-α2a: 1 Year follow-up of the OSST Study
Antiviral Therapy · 2016-05 · 21 (4) · 337-344
DOI: 10.3851/imp3019 ↗Abstract
Background In the OSST study, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who switched from long-term entecavir (ETV) therapy to pegylated interferon-α2a (PEG-IFN-α2a; 40 kDa) achieved higher rates of HBeAg seroconversion and hepatitis B surface antigen (HBsAg) loss than those who continued ETV. Herein we report the sustainability of serological responses during 1 year of untreated follow-up in patients who switched from ETV to PEG-IFN-α2a therapy. Methods A total of 62 patients who completed 48 weeks of PEG-IFN-α2a therapy were followed-up for 48 weeks off treatment. Primary end points were HBeAg seroconversion and maintenance of HBeAg seroconversion at 48 weeks post-treatment. Secondary end points included HBsAg loss, HBV DNA
EUVIMED